Last reviewed · How we verify
ATN-224
At a glance
| Generic name | ATN-224 |
|---|---|
| Sponsor | Attenuon |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Tetrathiomolybdate (TM) Plus Capecitabine (PHASE1, PHASE2)
- Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer (PHASE2)
- Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 (PHASE2)
- Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease (PHASE3)
- Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants (PHASE1)
- Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. (PHASE1)
- A Study of the Cardiac Effects of ALXN1840 in Healthy Adults (PHASE1)
- Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATN-224 CI brief — competitive landscape report
- ATN-224 updates RSS · CI watch RSS
- Attenuon portfolio CI